Topics

Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer

19:00 EST 7 Nov 2019 | Breast Cancer Research

Alteration of the PI3K/AKT/mTOR pathway is a common genomic abnormality detected in triple-negative breast cancer (TNBC). Everolimus acts synergistically with eribulin in TNBC cell lines and xenograft models. ...

Original Article: Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer

NEXT ARTICLE

More From BioPortfolio on "Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer"

Quick Search

Relevant Topic

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...